These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 9254534)

  • 21. Insulin and the prevention of insulin-dependent diabetes mellitus.
    Coutant R; Carel JC; Timsit J; Boitard C; Bougnères P
    Diabetes Metab; 1997 Sep; 23 Suppl 3():25-8. PubMed ID: 9342539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developments in the prediction of type 1 diabetes mellitus, with special reference to insulin autoantibodies.
    Franke B; Galloway TS; Wilkin TJ
    Diabetes Metab Res Rev; 2005; 21(5):395-415. PubMed ID: 15895384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Unitarian Hypothesis for the aetiology of diabetes mellitus.
    Morrison EY; Ragoobirsingh D; Peter SA
    Med Hypotheses; 2006; 67(5):1115-20. PubMed ID: 16806731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunologic and genetic aspects of latent autoimmune diabetes in the adult].
    Falorni A
    Minerva Endocrinol; 2003 Dec; 28(4):297-312. PubMed ID: 14752400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunoprevention of Type I diabetes mellitus].
    Spinas GA
    Ther Umsch; 1996 Dec; 53(12):882-8. PubMed ID: 9036566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune mechanisms in type 1 diabetes.
    Knip M; Siljander H
    Autoimmun Rev; 2008 Jul; 7(7):550-7. PubMed ID: 18625444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent.
    Tisch R; Wang B; Serreze DV
    J Immunol; 1999 Aug; 163(3):1178-87. PubMed ID: 10415012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-peptide and autoimmune markers in diabetes.
    Törn C
    Clin Lab; 2003; 49(1-2):1-10. PubMed ID: 12593469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I insulin dependent diabetes: an autoimmune disease that can be arrested or prevented with immunotherapy?
    Winter WE; Maclaren NK
    Adv Pediatr; 1985; 32():159-75. PubMed ID: 3909773
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies.
    Mallone R; Ortolan E; Pinach S; Volante M; Zanone MM; Bruno G; Baj G; Lohmann T; Cavallo-Perin P; Malavasi F
    Diabetologia; 2002 Dec; 45(12):1667-77. PubMed ID: 12488956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Genetic engineering approaches to the study of insulin-dependent diabetes mellitus markers].
    Pankov IuA
    Vopr Med Khim; 1997; 43(5):349-55. PubMed ID: 9446325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies in Type 1 diabetes.
    Schmidt KD; Valeri C; Leslie RD
    Clin Chim Acta; 2005 Apr; 354(1-2):35-40. PubMed ID: 15748597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What do epidemiologic observations tell us about the etiology of insulin dependent diabetes mellitus?
    Drash AL
    Schweiz Med Wochenschr; 1990 Jan; 120(3):39-45. PubMed ID: 2405477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for preventing type I diabetes mellitus.
    Verge CF; Eisenbarth GS
    West J Med; 1996 Mar; 164(3):249-55. PubMed ID: 8775937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The endocrine pancreas].
    Cortesão L; Saraiva AM; Guerreiro L
    Acta Med Port; 1995 Jun; 8 Suppl 1():S47-53. PubMed ID: 7653306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapeutic management of juvenile diabetes mellitus].
    Moncada E
    Rev Esp Fisiol; 1989; 45 Suppl():301-8. PubMed ID: 2701766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of predicting IDDM.
    Hahl J; Simell T; Ilonen J; Knip M; Simell O
    Diabetologia; 1998 Jan; 41(1):79-85. PubMed ID: 9498634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the immunointervention of type-1 diabetes mellitus.
    Schernthaner G
    Horm Metab Res; 1995 Dec; 27(12):547-54. PubMed ID: 8750784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological aspects of diabetes mellitus: prospects for pharmacological modification.
    Itoh M
    Pharmacol Ther; 1989; 44(3):351-406. PubMed ID: 2519348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.